AstraZeneca Sipavibart COVID-19 Prevention Drug Advances in EU

17 views
AstraZeneca stated that the European Union medicines regulator has accepted their market authorisation application for sipavibart.
AstraZeneca stated that the European Union medicines regulator has accepted their market authorisation application for sipavibart.

AstraZeneca announced Monday that the European Union drug regulator had accepted its market authorization application for accelerated assessment for sipavibart, an investigational COVID-19 prevention drug.

The submission was supported by positive data from a late-stage trial demonstrating sipavibart’s efficacy in reducing the risk of infection among patients with compromised immune systems.

Accelerated Assessment Granted:

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) granted sipavibart accelerated assessment status, citing its significant potential for public health impact and therapeutic innovation.

AstraZeneca acquired sipavibart from RQ Bio in May 2022, underscoring its commitment to expanding its portfolio of COVID-19 treatments.

COVID-19 Vaccine Withdrawal:

Earlier this year, AstraZeneca withdrew its COVID-19 vaccine from circulation, citing an oversupply of updated vaccines amidst the ongoing pandemic.

This move highlights AstraZeneca’s strategic focus on advancing new therapies like sipavibart to address evolving healthcare needs related to COVID-19.

James Adam

James Adam, a noted business writer for CEO Times Magazine, specializes in insightful industry analysis and executive profiles. Known for his clear, concise style, James offers readers an expert perspective on global business trends and market dynamics.

Previous Story

Shein IPO Plans: London vs. Hong Kong Amidst Controversy

Next Story

Anglo American Faces Setback with Grosvenor Coal Mine Fire

Latest from News